More on HALO
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $121.51 |
|
|||
| Open | $122.19 | ||||
| 52 Wk High | $18.39 | ||||
| 52 Wk Low | $6.96 | ||||
| Day High | $122.45 | ||||
| Day Low | $120.19 | ||||
| P/E | N/A | ||||
| EPS | $-0.58 | ||||
| Volume | 2,082,593 | ||||
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)
- Halozyme Therapeutics (HALO) PT Raised to $130 at TD Cowen
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Form 4 HALOZYME THERAPEUTICS, For: Oct 06 Filed by: Torley Helen
- Form 4/A HALOZYME THERAPEUTICS, For: May 05 Filed by: Connaughton Bernadette
- Halozyme Therapeutics (HALO) PT Raised to $78 at JPMorgan
- Halozyme stock rises after winning injunction against Merck
- Dutch court orders Merck to halt Keytruda SC sales in 8 countries
- Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
Entities mentioned with HALO
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- FDA | View Related Stories »
- S3 | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
